Oncology & Cancer
Targeted drug not approved for certain lymphoma patients on the NHS
People with a certain type of lymphoma will not be able to receive a targeted cancer drug on the NHS in England.
Dec 21, 2018
0
3
Lymphoma
Oncology & Cancer
Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...
Dec 17, 2018
0
43
Oncology & Cancer
ASH: A+CHP bests CHOP for peripheral T-cell lymphoma
(HealthDay)—For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone ...
Dec 5, 2018
0
0
Oncology & Cancer
New tool to find and fight most dangerous types of lymphoma
UK scientists have found a new way to identify people with the most aggressive types of lymphoma who are less likely to respond to standard drugs.
Dec 3, 2018
0
32
Oncology & Cancer
Study shows promise for fighting relapsed blood cancer with CAR-T immunotherapy, chemotherapy
University of North Carolina Lineberger Comprehensive Cancer Center researchers reported promising early results from a clinical study of an investigational cellular immunotherapy that used a patient's own, genetically engineered ...
Dec 3, 2018
0
3
Oncology & Cancer
New two-year data show 39 percent of NHL patients treated with CAR T remain in remission
A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta (axicabtagene ciloleucel) remained in remission ...
Dec 3, 2018
0
1
Oncology & Cancer
Combination immunotherapy shows high activity against recurrent Hodgkin lymphoma
A new combination of three drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase ...
Dec 3, 2018
0
3
Oncology & Cancer
Studies suggest immunotherapy adds punch to earlier attempts
New drugs that harness the body's immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists ...
Dec 2, 2018
0
3
Oncology & Cancer
Quality of life at diagnosis may predict survival for patients with aggressive lymphoma
Self-reported quality of life among patients diagnosed with aggressive lymphoma can predict overall survival and event-free survival, a Mayo Clinic study has found. The results were presented at the 56th American Society ...
Jul 9, 2018
0
0
Oncology & Cancer
New drugs are improving survival times for patients with aggressive type of blood cancer, study finds
Survival times for a highly aggressive type of blood cancer have nearly doubled over the last decade due to the introduction of new targeted drugs, a Yorkshire study has shown.
Jun 25, 2018
0
83
